Last reviewed · How we verify
Intranasal Influenza Live Attenuated Vaccine
This live attenuated influenza vaccine stimulates immune responses by delivering weakened influenza virus strains intranasally to induce mucosal and systemic immunity.
This live attenuated influenza vaccine stimulates immune responses by delivering weakened influenza virus strains intranasally to induce mucosal and systemic immunity. Used for Influenza prevention in children and adults.
At a glance
| Generic name | Intranasal Influenza Live Attenuated Vaccine |
|---|---|
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Drug class | Live attenuated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains temperature-sensitive, attenuated influenza virus strains that replicate in the cooler upper respiratory tract but are unable to cause disease. This replication triggers both mucosal IgA antibodies and systemic cellular and humoral immune responses, providing protection against circulating influenza viruses. The intranasal route mimics natural infection and generates broader, more durable immunity compared to inactivated vaccines.
Approved indications
- Influenza prevention in children and adults
Common side effects
- Nasal congestion
- Runny nose
- Sore throat
- Cough
- Fever
- Headache
Key clinical trials
- Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection (PHASE4)
- Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection (PHASE1)
- Intranasal LAIV Mucosal Immunity Examination (PHASE4)
- Mucosal and Systemic Immune Responses Induced by an Intranasal Influenza Live Attenuated Vaccine (PHASE4)
- Characterizing the Human Airway Immune Response to FluMist Vaccination (PHASE4)
- Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine (PHASE1)
- GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE (NA)
- The Interaction Between Mucosal Microbiota Colonization and the Immune Response to an Intranasal Influenza Live Attenuated Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |